Oslo, Norway, January 31st, 2023 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers last year submitted three abstracts to ECCMID, one of the most influential conferences in the field of microbiology and infectious diseases. The meeting attracted more than 14.000 participants in 2022 and is taking place 15-18th April in Copenhagen this year. All Adjutec abstracts were accepted.
In one presentation, the company lead compound (APC148) in combination with a broad-spectrum antibiotic, shows low frequencies of resistance in the tested bacterial strains. This is an important result that suggests high efficacy with minimal development of drug resistance in clinical use. The results will be presented by Veronika Smith, Dept of Pharmacy, University of Oslo (UiO).
In two presentations, our next-generation resistance breaker (APC247) in combination with a broad-spectrum antibiotic, showed promising in-vitro and in-vivo results. The combination restored antimicrobial susceptibility in >90% of the resistant bacterial strains tested. When tested in mouse infection models, the drug combination supported the effects found in-vitro. Both in-vitro and in-vivo testing with APC247 in combination with a broad-spectrum antibiotic show superior efficacy to the antibiotic alone. This will be tested further in in-vivo infection models. The results will be presented by Rebekka Rolfsnes, Dept of Pharmacy, UiO and Jon Ulf Hansen, Statens Serum Institut (SSI), Copenhagen
In one presentation, the company lead compound (APC148) in combination with a broad-spectrum antibiotic, shows low frequencies of resistance in the tested bacterial strains. This is an important result that suggests high efficacy with minimal development of drug resistance in clinical use. The results will be presented by Veronika Smith, Dept of Pharmacy, University of Oslo (UiO).
In two presentations, our next-generation resistance breaker (APC247) in combination with a broad-spectrum antibiotic, showed promising in-vitro and in-vivo results. The combination restored antimicrobial susceptibility in >90% of the resistant bacterial strains tested. When tested in mouse infection models, the drug combination supported the effects found in-vitro. Both in-vitro and in-vivo testing with APC247 in combination with a broad-spectrum antibiotic show superior efficacy to the antibiotic alone. This will be tested further in in-vivo infection models. The results will be presented by Rebekka Rolfsnes, Dept of Pharmacy, UiO and Jon Ulf Hansen, Statens Serum Institut (SSI), Copenhagen
Photo: Rebekka Rolfsnes, Senior Scientist @AdjuTec Pharma
"Our products target bacterial enzymes that destroy antibiotics, preserving antibiotic efficacy. Adjutec drug candidates addresses WHO priority pathogens. New products are highly needed as antibiotic resistance is increasing on a global scale. Adjutec continues to report encouraging efficacy results that will increase value for our shareholders. Preparations are on track for embarking on the phase 1 program with our lead compound APC148" comments Bjørn Klem.
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health threat that kills 1.27mill people every year. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main drivers in the development of drug-resistant pathogens. Lack of clean water, sanitation and inadequate infection prevention and control promote the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com
Follow us on LinkedIn and Twitter